This Article Full Text Full Text (PDF) All Versions of this Article: 49/5/971    most recent HYPERTENSIONAHA.107.087254v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dries, D. L. Search for Related Content PubMed PubMed Citation Articles by Dries, D. L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Other myocardial biology Congestive Hypertrophy Other Vascular biology Related Article

(Hypertension. 2007;49:971.)
© 2007 American Heart Association, Inc.

Editorial Commentaries

Relevance of Molecular Forms of Brain Natriuretic Peptide for Natriuretic Peptide Research

Daniel L. Dries

From the Penn Cardiovascular Institute, University of Pennsylvania, Philadelphia.

Correspondence to Daniel L. Dries, Penn Cardiovascular Institute, University of Pennsylvania, 6 Penn Tower, 3400 Spruce St, Philadelphia, PA 19104. E-mail daniel.dries@uphs.upenn.edu

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The focus on brain natriuretic peptide (BNP) as a biomarker, the elevation of which is associated with adverse outcomes in persons with heart failure, has obscured recognition of the myriad beneficial and compensatory biological actions provided by this small peptide hormone. Both atrial and ventricular cardiomyocytes synthesize and release both atrial natriuretic peptide (ANP) and BNP in response to volume or pressure overload, most specifically, an increase in myocardial transmural distending pressure. These peptide hormones activate the natriuretic peptide receptor type A, which contains a guanylate–cyclase domain, and this leads to the production of cGMP and the activation of downstream signaling cascades. The resulting biological actions in target tissue include the following actions that are universally beneficial in the setting of hypertension, hypertensive heart disease, and heart failure: venous and arterial vasodilation, maintenance of appropriate intravascular volume by promoting natriuresis, opposing activation of the renin–angiotensin–aldosterone system, reduced secretion of endothelin, and attenuation of central and peripheral sympathetic activity.¹ In addition, the natriuretic peptide system (NPS) functions as an autocrine/paracrine system that opposes the development of cardiac fibrosis and hypertrophy via pressure-independent mechanisms.²

BNP is produced as prohormone that undergoes further processing (Figure). After removal of the 26 amino acid signal peptide from the prepro-BNP molecule, pro-BNP (1-108) is secreted from cardiomyocytes and interacts with an enzyme called corin, a transmembrane serine protease produced in cardiomyocytes, resulting in the production of a 76 amino acid amino terminal fragment (NT-BNP 1-76) and the biologically active 32 amino acid carboxyl fragment . . . [Full Text of this Article]

Related Article:

Immunoreactivity and Guanosine 3',5'-Cyclic Monophosphate Activating Actions of Various Molecular Forms of Human B-Type Natriuretic Peptide

Denise M. Heublein, Brenda K. Huntley, Guido Boerrigter, Alessandro Cataliotti, Sharon M. Sandberg, Margaret M. Redfield, and John C. Burnett, Jr
Hypertension 2007 49: 1114-1119. [Abstract] [Full Text] [PDF]